RxRights Statement in Response to Google Settling Pharmacy Ad Probe for $500 Million

WASHINGTON--(BUSINESS WIRE)-- In response to today’s announcement that Google has settled the U.S. Justice Department’s pharmacy ad probe, Lee Graczyk, lead organizer of RxRights, issued the following statement:

“It is imperative to make the distinction that not all Canadian pharmacies are dangerous rogue sites. There are licensed, legitimate Canadian and other international pharmacies that Americans rely on to import safe, affordable prescription medications. Many Americans require these daily medications to treat conditions such as high blood pressure, diabetes and high cholesterol.

“These legitimate pharmacies are accredited through organizations such as Pharmacy Accreditation Services, Pharmacy Checker and the Canadian International Pharmacy Association.

“In addition, there are several key indicators Americans should check for when choosing an online pharmacy. They should verify that the pharmacy requires a signed, valid doctor’s prescription to purchase medications and that there is a licensed pharmacist to receive orders and answer questions.

“Legitimate Canadian online pharmacies should not have to bear the brunt for the unlawful importation of uncontrolled substances by dangerous rogues.”

About RxRights

RxRights is a national coalition of individuals and organizations concerned with the high cost of prescription drugs in the U.S. For more information, visit www.RxRights.org.



CONTACT:

RxRights
Lee Graczyk, 1-866-703-5442
[email protected]

KEYWORDS:   United States  North America  Canada  District of Columbia

INDUSTRY KEYWORDS:   Technology  Internet  Health  Public Policy/Government  Pharmaceutical  Public Policy  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.